<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949074</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00877-34</org_study_id>
    <nct_id>NCT04949074</nct_id>
  </id_info>
  <brief_title>Collection of RNA Extracted From Nasopharyngeal and Saliva Samples From Same Patients With Suspicion of Covid-19</brief_title>
  <acronym>COLL001</acronym>
  <official_title>Collection of SARS-CoV-2 RNA Extracted From Nasopharyngeal and Saliva Samples From Same Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ID Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ID Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constitution of a collection of SARS-CoV-2 RNA extracts from nasopharyngeal and saliva /&#xD;
      sputum samples, from the same patients (paired samples), taken during the same consultation&#xD;
      in an indication of detection of SARS-CoV-2 in with a view to developing tests / diagnostic&#xD;
      tools for SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to preserve their anonymity, the participant will be identified in a dedicated form&#xD;
      by a unique identification number. An identification list of participants will be kept in the&#xD;
      investigator's file. The investigator will ensure that the anonymity of each person&#xD;
      participating in the research is guaranteed.&#xD;
&#xD;
      The source documents are the original documents, data and files from which the data&#xD;
      concerning the participant is reported in the Data set_COLL001.xls form provided to the&#xD;
      investigator which will serve as an observation notebook.&#xD;
&#xD;
      The investigator must agree to allow direct access to research source data during monitoring,&#xD;
      audit or inspection visits. The source data is for the most part computerized and accessible&#xD;
      after authorization.&#xD;
&#xD;
      The data will be transcribed into an Excel form Data set_COLL001.xls pseudonymized form which&#xD;
      will serve as an observation book. The data will be recorded and then transmitted to ID&#xD;
      SOLUTIONS via the Data set_COLL001.xls form provided to the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Months</target_duration>
  <primary_outcome>
    <measure>collection of RNA extracted nasopharyngeal and saliva samples</measure>
    <time_frame>up to 1 month over which the samples of each participant are collected then tested</time_frame>
    <description>The expected outcome is&#xD;
The study will allow a collection of n=130 positive n=130 negative RNA extracted from both nasopharyngeal and saliva samples from patients with suspicious COVID-19 will enter the collection&#xD;
No immediate outcome is expected for patients enrolled in the study</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>RNA extracted from Positive NSP samples</arm_group_label>
    <description>RNA extracted from NSP samples, found positive for the presence of SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNA extracted from Positive saliva samples</arm_group_label>
    <description>RNA extracted from saliva samples found positive for the presence of SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNA extracted from negative NSP samples</arm_group_label>
    <description>RNA extracted from NSP samples, found negative for the presence of SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNA extracted from negative saliva samples</arm_group_label>
    <description>RNA extracted from saliva samples found negative for the presence of SARS-CoV-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saliva sampling</intervention_name>
    <description>when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked</description>
    <arm_group_label>RNA extracted from Positive saliva samples</arm_group_label>
    <arm_group_label>RNA extracted from negative saliva samples</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA extracted from nasopharyngeal and saliva / sputum extracts from the same patients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for SARS-CoV-2 screening&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, female adult&#xD;
&#xD;
          -  Patient with an indication for SARS-CoV-2 screening.&#xD;
&#xD;
          -  Patient having been informed and having given his non-objection to participate in the&#xD;
             study&#xD;
&#xD;
          -  Patient affiliated with a French social security scheme or beneficiary of such a&#xD;
             scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Vulnerable people Adults placed under tutorship or curatorship or under judicial&#xD;
             protection, Patient unable to personally give consent, or adult protected by law,&#xD;
             Opposition expressed to inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy M Bayette, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Labosud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy M Bayette, Dr</last_name>
    <phone>+33467207913</phone>
    <email>jeremy.bayette@labosud.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labosud</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremy M Bayette, Dr</last_name>
      <phone>+33 (0)4 67 20 79 13</phone>
      <email>jeremy.bayette@labosud.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>saliva</keyword>
  <keyword>diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>the data will not be shared to other researchers since the research is an internal collection of samples; for ID SOLUTIONS</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

